Financials data is unavailable for this security.
View more
Year on year Shanghai Pharmaceuticals Holding Co Ltd grew revenues 5.75% from 260.30bn to 275.25bn while net income improved 20.82% from 3.77bn to 4.55bn.
| Gross margin | 10.35% |
|---|---|
| Net profit margin | 2.43% |
| Operating margin | 3.49% |
| Return on assets | 2.97% |
|---|---|
| Return on equity | 7.70% |
| Return on investment | 8.24% |
More ▼
Cash flow in CNYView more
In 2024, Shanghai Pharmaceuticals Holding Co Ltd increased its cash reserves by 15.93%, or 4.38bn. The company earned 5.83bn from its operations for a Cash Flow Margin of 2.12%. In addition the company generated 415.98m cash from investing, though they paid out 1.86bn more in financing than they received.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 23.11 |
|---|---|
| Tangible book value per share | 16.44 |
More ▼
Balance sheet in CNYView more
| Current ratio | 1.32 |
|---|---|
| Quick ratio | 1.02 |
| Total debt/total equity | 0.7088 |
|---|---|
| Total debt/total capital | 0.3747 |
More ▼
Growth rates in CNY
SmartText is unavailable
| Div yield(5 year avg) | -- |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 19.05% |
| EPS growth(5 years) | -3.06 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 39.89 |
More ▼
